KRMD

Rating neutralAI Memo

KORU Medical

As of 2026-07-23/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-23 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Second-quarter 2026 results scheduled • 2026-08-05

Expected move: +0%

Biggest risk

The deterministic prior turned negative, while gross margin declined to 61.5% because of production timing and tariff-related charges. Cash generation remains a key test, and low coverage leaves limited independent confirmation of forward estimates or revisions.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

Q1 showed strong revenue growth, international momentum, core-market share gains, and improving loss metrics. Continued prefilled-syringe conversions and clinical-trial adoption could support the reiterated outlook and longer-term platform expansion.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-23

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Execution against reiterated 2026 outlook
Expansion beyond core SCIg applications
Supply continuity and second-site qualification

BearKey bullets

510(k) and Phase III collaboration outcomes have uncertain timing and commercial conversion.
Dependence on distributor purchases and successful qualification of a second manufacturing site.
Gross-margin pressure from production timing, tariffs, and possible unfavorable mix.

WatchKey bullets

Second-quarter 2026 results scheduled

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $4 (p=50%)

Bull/Bear spread: +67% / -29%

Vs latest close: Bull +67% · Base +0% · Bear -29%

Scenario probabilities

Bull Target: $7 (p=20%)Base Target: $4 (p=50%)Bear Target: $3 (p=30%)

Commentary

Company-source news is constructive on Q1 growth and reiterated guidance, but the deterministic signal is negative and the stock remains low coverage. Consensus surprise, analyst revisions, post-print price attribution, options, short interest, employee sentiment, and usable social coverage are unavailable; sentiment therefore supports monitoring rather than a high-conviction rerating thesis.

As of 2026-07-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Execution against reiterated 2026 outlook
Expansion beyond core SCIg applications
Supply continuity and second-site qualification

Scenarios

Bull Target (Scenario probability)

$7 / p=20% prob

Base Target (Scenario probability)

$4 / p=50% prob

Bear Target (Scenario probability)

$3 / p=30% prob

Price $4 as of 2026-07-27

Nearest Scenario: Base (∆ 0%)

Targets vs latest close: Bull +67% · Base +0% · Bear -29%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-05
Second-quarter 2026 results scheduled
KORU announced it will report second-quarter 2026 results on August 5, 2026. The release is a defined near-term information event, but consensus, surprise magnitude, and post-print analyst reaction are unavailable [#PR-EARNINGS-2026-07-15].
Prob 100.00% • Move 8.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Execution against reiterated 2026 outlook
2026-12-31
Q1 revenue grew 22.1% year over year to $11.8 million, while management reiterated 2026 revenue of $47.5-$50.0 million, 61%-63% gross margin, positive adjusted EBITDA, and positive cash flow. The key test is whether share gains, international prefilled-syringe conversions, and clinical-trial revenue persist [#SEC-8K-2026-05-06].
Prob 57% • Move 12% • Priced-in 60%

Long-term Catalysts

Months to a year

Expansion beyond core SCIg applications
2027-07-23
KORU submitted a 510(k) application for deferoxamine use of the Freedom Infusion System, and two non-Ig pharmaceutical collaborations advanced to Phase III trials. Regulatory and commercial timing remains uncertain [#SEC-8K-2026-05-06].
Prob 48% • Move 15% • Priced-in 30%
Supply continuity and second-site qualification
2027-12-31
The amended Command Medical agreement extends the initial term to December 31, 2031 and requires qualification of a second manufacturing site by December 31, 2027. This supports supply continuity but creates a measurable execution dependency [#8-K-2026-06-30].
Prob 70% • Move 8% • Priced-in 45%

Risks

510(k) and Phase III collaboration outcomes have uncertain timing and commercial conversion.
Dependence on distributor purchases and successful qualification of a second manufacturing site.
Gross-margin pressure from production timing, tariffs, and possible unfavorable mix.
Low analyst coverage and unavailable post-earnings revision, options, short-interest, and social data reduce confidence.
Reiterated positive adjusted EBITDA and cash-flow targets may not be achieved if growth or conversion timing weakens.

Peers

Symbol	Summary
INFU	Closest same-sector, similar-market-cap comparator in the packet, though the packet does not establish a direct product or valuation relationship.
INGN	Similar-market-cap health-care equipment comparator; useful only as a loose small-cap medtech reference.
ABT	Large medtech benchmark for scale and recurring medical-device demand, but not a valuation peer for KRMD.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-23

AI Stock Memo: KRMD - KORU Medical - RankAlpha